CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced scientific presentations and late-breaking clinical data on Barostim at THT 2026, March 2-4 in Boston. Key items include six-month outcomes from the REBALANCE Registry in over 400 patients, updates from BREATHE-HF, and initiation of the BENEFIT-HF trial.
The company will host a satellite program March 3, 12:15-1:30 p.m. ET, and said BENEFIT-HF has CMS Category B IDE coverage with enrollment expected to begin in the first half of 2026.
Positive
- REBALANCE Registry: six-month outcomes in over 400 patients
- BENEFIT-HF: trial initiated with CMS Category B IDE coverage; enrollment expected H1 2026
- Late-breaking data: Barostim featured in THT 2026 scientific sessions and posters
Negative
- None.
News Market Reaction – CVRX
On the day this news was published, CVRX gained 0.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CVRX was up 1.24% while scanner activity showed only MASS moving, down -14.100000262260435%. Broader device peers (e.g., BSGM +39.91%, ELMD -0.59%, SGHT -1.15%, STIM -4.29%, TLSI -4.71%) were mixed, pointing to a stock-specific reaction to Barostim data visibility rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Q4/FY25 earnings | Positive | -13.0% | Reported FY25 revenue of $56.7M with 85% gross margin and 2026 guidance. |
| Jan 29 | Earnings call date | Neutral | -2.3% | Announced timing and access details for Q4 2025 earnings call and webcast. |
| Jan 22 | BENEFIT-HF initiation | Positive | +11.4% | Initiated BENEFIT-HF randomized trial in expanded heart failure population. |
| Jan 12 | Prelim results/guidance | Neutral | -9.9% | Issued preliminary FY25 revenue ranges and 2026 guidance with updated costs. |
| Jan 06 | Reimbursement update | Positive | +3.3% | Confirmed implementation of Category I CPT codes for Barostim therapy. |
News tied to Barostim trials and reimbursement (e.g., BENEFIT-HF, Category I CPT codes) has generally aligned with positive price moves, while earnings updates have sometimes triggered sell-offs despite growth.
Over the last few months, CVRx has highlighted steady Barostim commercialization and a growing clinical footprint. Full-year 2025 revenue reached $56.7M with an 85% gross margin and 252 active U.S. implanting centers. The company launched the pivotal BENEFIT-HF trial targeting 2,500 patients and secured permanent Category I CPT codes effective Jan 1, 2026. This THT 2026 update extends that narrative by emphasizing real-world Barostim outcomes, registries, and additional heart failure studies presented at a major specialty meeting.
Regulatory & Risk Context
CVRx has an effective Form S-3 shelf filed on Nov 6, 2025 to offer up to $150,000,000 of various securities, with one recorded usage via a 424B5 prospectus supplement on Jan 12, 2026. This structure, alongside the existing ATM program, provides flexibility to raise capital via equity or other securities through future prospectus supplements.
Market Pulse Summary
This announcement highlights expanding clinical and real‑world evidence for Barostim, including six‑month REBALANCE Registry outcomes in over 400 patients and multiple heart failure presentations at THT 2026. It builds on recent milestones such as the large BENEFIT‑HF randomized trial and permanent Category I CPT reimbursement. Investors may watch for published efficacy and hospitalization data, registry expansions, uptake across implanting centers, and any additional financing moves under the existing $150,000,000 shelf and ATM program disclosed in recent filings.
Key Terms
neuromodulation medical
barostim medical
baroreflex activation therapy medical
left ventricular ejection fraction medical
lvef medical
hemodynamic medical
cms category b ide coverage regulatory
randomized study medical
AI-generated analysis. Not financial advice.
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts.
The presentations include late-breaking clinical data, oral sessions and posters highlighting real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements and changes in advanced hemodynamic, respectively.
Late-Breaking REBALANCE Registry Data
In a late-breaking presentation on Monday, March 2, Dr. Dmitry Yaranov will share, for the first time, data from the REBALANCE Registry, a post-market observational study designed to evaluate real-world data on the safety and benefit of Barostim therapy in the commercial setting. Dr. Yaranov will present the six-month outcomes in over 400 patients enrolled in the registry.
Scientific Presentations Featuring Barostim
Monday, March 2:
- Late-Breaking Clinical Science Session 1: Initial Six-Month Outcomes with Baroreflex Activation Therapy from the REBALANCE Registry (Dr. Dmitry Yaranov)
- Unmasking the Energetic Response Following Acute Titration of Baroreflex Activation Therapy Through Patient-Specific Modeling and Simulation (Dr. Rohan Goswami)
- Impact of Baroreflex Activation Therapy on Hospitalizations: A Single Center Retrospective Analysis (Dr. Joel Joseph)
Tuesday, March 3:
- Electrical Therapies for Heart Failure: Barostimulation for HFrEF (Dr. Philip Adamson)
- Abstract Session 8: Heart Failure Reduced Ejection Fraction I
- Real-World Outcomes of Barostim Baroreflex Activation Therapy in Heart Failure: Analysis of a Large Multi-Institutional Database (Dr. Arvind Bhimaraj)
- LVEF and Functional Improvement Observed in a Post-Market Registry of Barostim Baroreflex Activation Therapy (Dr. Dmitry Yaranov)
CVRx Sponsored Satellite Program
CVRx will also host a satellite program on Tuesday, March 3 from 12:15-1:30 p.m. ET in Ensemble CD South, which will include the following presentations:
- Advances in Evidence with Baroreflex Activation Therapy (Dr. Philip Adamson)
- Outcomes from the REBALANCE Registry (Dr. Dmitry Yaranov)
- BREATHE-HF: Impact of Barostim Therapy on Cardiac Hemodynamics
(Dr. Gabriel T. Sayer) - BENEFIT-HF: Broadening Access to Barostim Therapy (Dr. Farooq Sheikh)
During the satellite program, faculty will provide updates on the REBALANCE Registry, the BREATHE-HF trial, and the BENEFIT-HF trial. BREATHE-HF, a large physician-initiated study, is evaluating the impact of Barostim on cardiac hemodynamics. In January, CVRx announced the initiation of the BENEFIT-HF trial, a landmark randomized study supported by CMS Category B IDE coverage. The trial is designed to evaluate the impact of Barostim in a significantly expanded heart failure population, with the primary endpoint as a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026.
“We are excited by the new data supporting Barostim being featured at THT 2026,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are encouraged by the increasing adoption of Barostim by the heart failure community. The accelerating cadence of publications evaluating Barostim’s impact is proof of the positive patient impact and increasing acceptance of Barostim in the heart failure treatment continuum.”
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected enrollment of the BENEFIT-HF clinical trial and anticipated benefits of Barostim therapy. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our expectations regarding enrollment, the resulting impact of our addressable market and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
What REBALANCE Registry results did CVRx (CVRX) present at THT 2026?
When and where will CVRx present late-breaking Barostim data at THT 2026?
What is the BENEFIT-HF trial announcement from CVRx (CVRX)?
What topics are covered in the CVRx satellite program at THT 2026?
What is the BREATHE-HF study update CVRx reported at THT 2026?
How large was the patient sample CVRx reported from the REBALANCE Registry?
